STATEMENT: MolecuLight present at the Annual Conference of the European Wound Management Association (EWMA) 2024 (2)

(Information sent by the signatory company).

STATEMENT: MolecuLight present at the Annual Conference of the European Wound Management Association (EWMA) 2024 (2)

(Information sent by the signatory company)

-MolecuLight present in 11 presentations and posters at the European Wound Management Association (EWMA) Annual Conference 2024

Extensive clinical evidence using the MolecuLight imaging platform reveals its significant global adoption and proven utility in wound care

TORONTO and LONDON, May 1, 2024 /PRNewswire/ -- MolecuLight Inc., the leader in point-of-care digital wound measurement and real-time bacterial detection using fluorescence imaging, announces that its MolecuLight wound imaging platform features prominently in several presentations and posters at the European Wound Management Association (EWMA) Annual Conference 2024, taking place May 1-3, 2024 in London, United Kingdom. The EWMA Annual Meeting is the largest wound care conference in Europe and one of the most important events globally for wound care professionals.

"We are honored by the widespread adoption of MolecuLight point-of-care devices among physicians around the world, who see them as a highly valuable and transformative tool in their wound care practices," said Anil Amlani, CEO of MolecuLight. "The impressive collection of at least 11 talks and posters from multiple and diverse facilities worldwide shows how the MolecuLight imaging device is becoming a new standard of care in this specialty. The diverse range of presenters from North America, Europe and South America underscores the global reach of MolecuLight imaging technology. The clinical evidence shown at EWMA is reflected in more than 80 peer-reviewed publications worldwide, showing the significant benefit of MolecuLight i:X® and DX™ for clinical evaluation. of wounds. practice and results."

Dr. Jonathan Johnson, a wound care thought leader and health equity expert based in Washington, DC, will speak at EWMA about how MolecuLight's innovative technology overcomes disparities in wound assessment in dark skin tones. “It is critical to highlight healthcare barriers that disproportionately impact minority populations and EWMA provides the perfect forum to reach a global audience with this vital work.” When asked about his upcoming presentation, Dr. Johnson commented, "I am honored to share my latest research showing how MolecuLight improves bacterial detection in wounds regardless of skin tone, a critical limitation of traditional clinical evaluation." "This technology is helping to remove important barriers to equitable care. By supporting the adoption of MolecuLight imaging, we are paving the way for a healthier, more equitable future."

"As lead author of two studies that will be presented at this edition of EWMA with MolecuLight, I am delighted to show how fluorescence signals can revolutionize bacterial treatment and ultimately lead to optimized wound outcomes," said Rosemarie Derwin. , an experienced nurse, educator and researcher from Dublin, Ireland. "Our research underscores how essential adequate and objective bacterial clearance from the wound bed is in our efforts to achieve healing and ultimately improve the quality of life of our patients," she concluded.

The collection of 4 presentations and 7 posters featuring MolecuLight imaging devices show how clinical decision making is informed and improved through its digital wound measurement feature, detecting high bacterial load in wounds next to the bed and, surprisingly, its ability to monitor and track wound size and bioburden over time and minimize operator bias. The studies presented span the continuum of wound care, including:

The findings to be presented illustrate the significant clinical improvements in multiple aspects of wound care provided by the MolecuLight platform.

A selection of the clinical posters and presentations presented by the MolecuLight i:X and DX at the European Wound Management Association (EWMA) 2024 Annual Conference are as follows:

(a) Some clinical presentations and workshops that mention MolecuLight point-of-care devices include:

(b) Some clinical posters citing MolecuLight point-of-care devices include:

MolecuLight i:X and DX are the only imaging devices for real-time detection of elevated bacterial load in wounds that are FDA Class II cleared, CE marked, and Health Canada approved. With clinical evidence including more than 80 peer-reviewed publications, the devices are used by leading wound care centers globally.

About MolecuLight Inc.

MolecuLight Inc. is a privately held medical imaging company with a global presence offering fully commercialized point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging platform technology. MolecuLight's suite of commercial devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and accessories, have scientifically proven capabilities that improve wound care practices and outcomes across all service sites. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway that includes two CPT® codes for the physician's work to perform "fluorescence imaging for the presence, location and load of bacteria" and the facility's payment for the Hospital Outpatient Department (HOPD) and the Ambulatory Surgical Center (ASC) through an Ambulatory Payment Classification (APC) assignment.

CONTACT: Laura Jones-Donaldson, MolecuLight Inc.,, T. 1,416.542.5507,

Photo - -

View original content: